BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Senseonics Holdings (SENS) Issues FY24 Guidance
June 21, 2024 4:06 PM EDTSenseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced business updates and provided its full year 2024 financial outlook.
Business Updates
Reaffirmed global net revenue for the first half of 2024 is expected to be $10 million, representing growth of approximately 21% compared to the first half of 2023Generated over 200% more new patient starts in the US in the first half of 2024 compared to the first half of 2023FDA... More